We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

There is good reason to be optimistic about eliminating HIV/AIDS, says an editorial in New Scientist.

The strongest hope lies in a potential "cure" based on gene therapy, it says. US company Sangamo Biosciences is developing a gene therapy to emulate the effect of a bone marrow transplant that "vanquished" the virus in an HIV patient. If it works, patients could be cured with a single shot of gene therapy instead of a lifetime of antiretroviral therapy (ART), says the editorial.

And ARTs are themselves a reason for optimism, it adds. According to the WHO, existing ARTs could eliminate HIV in Africa by 2050 — if accompanied by regular testing and quick treatments. Such a long-term programme would be expensive but at US$85 billion, the cost is a fraction of the US$700 billion recently spent to bail out US banks.

And ART prices could fall. GlaxoSmithKline has said it will offer poor countries all its medicines at 25 per cent less than the typical price in the developed world.

With enough time and money, the editorial concludes we can finally start to rid the world of HIV/AIDS.

Link to full article in New Scientist